DNA旋转酶和拓扑异构酶IV是扎氟沙星在肺炎链球菌中的双重靶点。 - Suppr

Suppr

超能文献

DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.

作者信息

Park Hee Soo, Jung Sung Ji, Kwak Jin-Hwan, Choi Dong-Rack, Choi Eung-Chil

出版信息

Int J Antimicrob Agents. 2010 Jul;36(1):97-8. doi: 10.1016/j.ijantimicag.2010.02.022. Epub 2010 Apr 18.

DOI:10.1016/j.ijantimicag.2010.02.022

PMID:20403681

Abstract

摘要

相似文献

DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.

Int J Antimicrob Agents. 2010 Jul;36(1):97-8. doi: 10.1016/j.ijantimicag.2010.02.022. Epub 2010 Apr 18.

In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.

J Antimicrob Chemother. 2006 Dec;58(6):1279-82. doi: 10.1093/jac/dkl427. Epub 2006 Oct 20.

Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.

J Antimicrob Chemother. 2008 Jul;62(1):98-104. doi: 10.1093/jac/dkn136. Epub 2008 Apr 4.

Evaluation of melting curve analysis for screening the most prevalent mutations in topoisomerase genes from Streptococcus pneumoniae.

J Clin Microbiol. 2008 Jan;46(1):396-7; author reply 397. doi: 10.1128/JCM.01924-07.

Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.

J Antimicrob Chemother. 2003 Dec;52(6):944-52. doi: 10.1093/jac/dkg465. Epub 2003 Oct 29.

In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.

J Antimicrob Chemother. 2009 Dec;64(6):1226-9. doi: 10.1093/jac/dkp370. Epub 2009 Oct 14.

Streptococcus pneumononiae gyrase ATPase: development and validation of an assay for inhibitor discovery and characterization.

Anal Biochem. 2007 Jun 1;365(1):132-43. doi: 10.1016/j.ab.2007.02.029. Epub 2007 Feb 27.

Identification of a novel resistance mutation in parE that confers high-level resistance to moxifloxacin in Streptococcus pneumoniae.

J Antimicrob Chemother. 2012 Nov;67(11):2773-4. doi: 10.1093/jac/dks262. Epub 2012 Jul 3.

Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.

J Antimicrob Chemother. 2005 Oct;56(4):769-72. doi: 10.1093/jac/dki315. Epub 2005 Aug 26.

Contribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniae.

J Bacteriol. 2005 Feb;187(4):1536-40. doi: 10.1128/JB.187.4.1536-1540.2005.

引用本文的文献

You Win Some, You Lose Some: Modifying the Molecular Periphery of Nitrofuran-Tagged Diazaspirooctane Reshapes Its Antibacterial Activity Profile.

Int J Mol Sci. 2024 Dec 29;26(1):207. doi: 10.3390/ijms26010207.

A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.

Molecules. 2023 Feb 13;28(4):1762. doi: 10.3390/molecules28041762.

Mutational Diversity in the Quinolone Resistance-Determining Regions of Type-II Topoisomerases of Serovars.

Antibiotics (Basel). 2021 Nov 26;10(12):1455. doi: 10.3390/antibiotics10121455.

Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation.

Pharmaceutics. 2021 Aug 18;13(8):1289. doi: 10.3390/pharmaceutics13081289.

Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.

Microorganisms. 2020 Jan 30;8(2):191. doi: 10.3390/microorganisms8020191.

Pharmacotherapy of Lower Respiratory Tract Infections in Elderly-Focused on Antibiotics.

Front Pharmacol. 2019 Oct 31;10:1237. doi: 10.3389/fphar.2019.01237. eCollection 2019.

and Activity of Zabofloxacin and Other Fluoroquinolones Against MRSA Isolates from A University Hospital in Egypt.

Pol J Microbiol. 2019;68(1):59-69. doi: 10.21307/pjm-2019-007.

Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae.

Molecules. 2016 Nov 17;21(11):1562. doi: 10.3390/molecules21111562.

Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial.

Int J Chron Obstruct Pulmon Dis. 2015 Oct 22;10:2265-75. doi: 10.2147/COPD.S90948. eCollection 2015.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验